Mytrus Rolls Out Clinical Research Industry's First Patient-Friendly System for Informed Consen

Mytrus Rolls Out Clinical Research Industry's First Patient-Friendly System for Informed Consent via iPad(R) Application

ID: 132895

Interim Data in a Randomized Validation Study With Sutter Health Suggests the Mytrus iPad App Is More Effective for Patient Education During the Informed Consent Process


(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 04/09/12 -- , an innovative clinical technology and services company for medical and pharmaceutical research, today announced the debut of its iPad application explaining informed consent prior to clinical trial patient enrollment. Using animation and other visual imagery, the Mytrus iPad application is the first in the industry to condense the complex and critical disclosure information required at the start of a clinical trial into an easy-to-understand, digitized format. This new approach not only ensures better patient comprehension; it also helps researchers streamline the patient enrollment process for a more economical and quicker study start.

"The informed consent documents required at the initiation of a clinical trial are complicated; even with a clinician's help, patients find it difficult to understand and retain the information," explained Anthony Costello, chief operating officer for Mytrus. "Our iPad application simplifies the patient education process, giving sponsors better control of study starts and ensuring a better and more consistent continuum of care for enrolled subjects."

The Mytrus iPad application is now being rolled out globally for new and ongoing studies. Early adopters are noting that the application not only shortens the time required for patient enrollment; it ensures consistent patient education and comprehension of the informed consent process, an important consideration for multi-site and international studies.

Interim analysis data gleaned through a randomized trial conducted at Sutter Health's in San Francisco shows that patients using the Mytrus iPad application for informed consent have a significantly better understanding of clinical trial risks and processes. Twenty-four hours after completing the informed consent process, 76 percent of patients using the iPad application successfully passed a comprehension quiz; only 52 percent of patients using traditional paper-based forms demonstrated an understanding of the informed consent procedure. The difference between the groups is a statistically significant interim finding.





"The preliminary results from our randomized trial suggest that this new approach to the consent process may improve how well patients understand studies before they agree to join them," noted Michael C. Rowbotham, MD, scientific director for the California Pacific Medical Center Research Institute.

Using the Mytrus iPad application during the patient enrollment process is straightforward: Mytrus tailors the digitized informed consent documentation to fit the clinical trial protocol design and pre-loads the application to the required number of iPad devices. These devices are on loan to the study sites until the informed consent enrollment stage is complete. This easy deployment scenario ensures that any clinical trial, no matter how small, can improve the patient experience. Mytrus is also able to add the iPad consent process to ongoing studies still in the recruitment and enrollment stages.

A version of the Mytrus informed consent application based on the Android™ OS will be available in Q2 2012.

Founded in 2009, Mytrus is a San Francisco-based clinical technology and services company built on the idea that modern technologies can enable people to safely participate in clinical trials from the convenience of their own home, thereby improving accessibility, convenience and compliance, as well as cutting costs. Learn more about Mytrus at or find the company on and Twitter .





Contact:
Anthony Costello
Mytrus
(415) 216-1260

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Augme Files Patent Infringement Suit Against Competitor Millennial Media, Inc. Coventor's SEMulator3D 2012 Software Release Increases Speed and Accuracy of MEMS and Semiconductor Process Development
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 09.04.2012 - 12:00 Uhr
Sprache: Deutsch
News-ID 132895
Anzahl Zeichen: 0

contact information:
Town:

SAN FRANCISCO, CA



Kategorie:

Software



Diese Pressemitteilung wurde bisher 185 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Mytrus Rolls Out Clinical Research Industry's First Patient-Friendly System for Informed Consent via iPad(R) Application"
steht unter der journalistisch-redaktionellen Verantwortung von

Mytrus (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Mytrus Appoints Anthony Costello as CEO ...

SAN FRANCISCO, CA -- (Marketwire) -- 07/05/12 -- , an innovative clinical technology and services company for medical and pharmaceutical research, today announced that Anthony J. Costello has been appointed company CEO, effective immediately. He re ...

Alle Meldungen von Mytrus



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z